MedTrace Logo

Glucose Reduction by Early Acarbose Treatment in Basal Insulin

NCT00970528 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2014-02-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in combination with metformin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Acarbose (Glucobay, BAYG5421)

uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin

DRUG

Voglibose (Basen)

uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970528 on ClinicalTrials.gov